Definium Therapeutics' Single-Dose LSD Therapy Clears Second Phase 3 Trial for Generalized Anxiety Disorder
A single-dose formulation of LSD has met its primary endpoints in a second Phase 3 clinical trial, demonstrating rapid and sustained symptom relief for patients with generalized anxiety disorder. The results position the psychedelic compound as the first potentially new pharmacological mechanism for the condition in over two decades.
By Aylin Aksoy
How this story has developed
This report is part of a developing story — read the earlier chapters below.
- Phase 3 Trial Shows Psychedelic-Derived DT120 Achieves Rapid Remission for Generalized Anxiety Disorder
- Definium Therapeutics' Single-Dose LSD Therapy Clears Second Phase 3 Trial for Generalized Anxiety Disorder (this article)
- Clinical Researchers
- Focuses on the paradigm shift from daily dosing to single-dose therapies and the novel pharmacological mechanism.
- Biotech Investors
- Focuses on the commercial viability, FDA approval timeline, and market size for a new generalized anxiety disorder drug.
Perspectives this story doesn't cover
- Psychiatric patients currently managing treatment-resistant anxiety
- Health insurance actuaries evaluating coverage models for supervised psychedelic sessions
Fast facts
- Definium Therapeutics' single-dose LSD therapy, DT120, cleared its second Phase 3 trial for generalized anxiety disorder.
- The drug provided rapid and sustained symptom relief, meeting all primary clinical endpoints.
- If approved, it would be the first new pharmacological mechanism for generalized anxiety in over 20 years.
- The treatment previously received FDA Breakthrough Therapy designation.
Why this matters
Generalized anxiety disorder affects millions globally, but standard treatments like SSRIs often take weeks to work and carry significant side effects. A single-dose therapy that provides immediate, durable relief could fundamentally change how clinical psychiatry manages chronic anxiety.
How we got here
2024
The FDA grants Breakthrough Therapy designation to the single-dose LSD therapy for generalized anxiety disorder.
Early 2026
Definium Therapeutics reports positive topline data from its first Phase 3 trial of DT120.
September 24, 2026
The company releases data from the second Phase 3 trial, confirming the drug's efficacy and safety profile.
On September 24, 2026, Definium Therapeutics released the topline data for its second Phase 3 clinical trial of DT120, a single-dose LSD-based therapy for generalized anxiety disorder.[5]
The readout confirmed that the compound met its primary endpoints, demonstrating a statistically significant reduction in anxiety symptoms compared to a placebo.[3][5]
This marks the second consecutive late-stage trial where the psychedelic derivative provided rapid and sustained relief after just one administered dose, giving the drug a 3-for-3 success rate across its recent major clinical tests.[1][2]
Generalized anxiety disorder affects an estimated 6.8 million adults in the United States annually, yet the condition has not seen a fundamentally new class of pharmacological treatment approved in more than two decades.[1]
Current standard-of-care medications, primarily selective serotonin reuptake inhibitors, typically require daily dosing and take between four to six weeks to reach therapeutic efficacy.[1][4]
In contrast, the DT120 protocol involves a single supervised dosing session, after which patients in the trial reported sustained reductions in baseline anxiety metrics without the need for daily medication.[2][5]
The financial markets reacted to the clinical milestone on September 25, with analysts noting that the positive data could shift the narrative around Definium Therapeutics as it prepares for potential regulatory filings.[4]
The company is also evaluating the compound for other indications, recently highlighting parallel Phase 3 data for DT120 in treating major depressive disorder.[5][6]
The FDA previously granted Breakthrough Therapy designation to the treatment in 2024, an expedited pathway reserved for drugs that show substantial improvement over available therapies for serious conditions.[2]
Viewpoints in depth
Clinical Researchers
Focuses on the paradigm shift from daily dosing to single-dose therapies and the novel pharmacological mechanism.
For clinical researchers and psychiatrists, the success of DT120 represents a potential structural shift in how anxiety is managed. Rather than prescribing daily SSRIs that alter serotonin levels over weeks and often bring side effects like emotional blunting or weight gain, a single-dose psychedelic session aims to reset neural pathways rapidly. The medical community is closely watching the safety data to understand how these supervised sessions can be scaled across standard psychiatric practices.
Biotech Investors
Focuses on the commercial viability, FDA approval timeline, and market size for a new generalized anxiety disorder drug.
Financial analysts view the consecutive Phase 3 wins as a major de-risking event for Definium Therapeutics. With generalized anxiety disorder affecting millions and no fundamentally new drug classes approved in two decades, the total addressable market is massive. However, investors are also modeling the logistical challenges of commercializing a drug that requires a supervised clinical setting, which introduces different reimbursement and infrastructure hurdles compared to traditional pharmacy prescriptions.
Sources
Source coverage
6 outlets
2 viewpoints surfaced
- [1]Health and MeClinical Researchers
LSD-Based Treatment Clears Second Phase 3 Trial: Could It Be The First New GAD Drug In 2 Decades?
Read on Health and Me → - [2]Biotech MorningClinical Researchers
An LSD Pill Just Went 3-for-3 in the Biggest Test of Psychedelic Medicine
Read on Biotech Morning → - [3]The PharmaletterClinical Researchers
Definium reports third positive Phase III readout for LSD anxiety drug
Read on The Pharmaletter → - [4]Simply Wall St.Biotech Investors
Will Positive Phase 3 Anxiety Data Change Definium Therapeutics' (DFTX) Narrative
Read on Simply Wall St. → - [5]MarketBeatBiotech Investors
Definium Therapeutics Highlights Phase III DT120 Gains in Anxiety and Depression
Read on MarketBeat → - [6]HealthesystemsClinical Researchers
Emerging Therapies: Phase 3 Data for LSD-Based Drug in Major Depression
Read on Healthesystems →
Comments
More in Health
See all →Cardiovascular Health
Landmark Trial Finds Vitamin K2 and D3 Slow Coronary Artery Calcification by 21%
5 sources
Longevity Science
Major Analysis Finds Prescription Drugs and Lifestyle Changes, Not Supplements, Reduce Biological Age
5 sources
Childhood Obesity
Novo Nordisk and UNICEF Expand $18 Million Initiative to Prevent Childhood Obesity in Seven Countries
5 sources
Gene Therapy
FDA Reverses Course to Clear Path for Landmark Huntington's Gene Therapy
4 sources
Every angle. Every day.
Get Health stories with full source coverage and perspective breakdowns delivered to your inbox.